Prohance is a drug owned by Bracco Diagnostics Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 08, 2015. Details of Prohance's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5846519 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(8 years ago) |
Expired
|
| US5474756 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) |
Expired
|
| US6143274 | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Prohance is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prohance's family patents as well as insights into ongoing legal events on those patents.
Prohance's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prohance's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 08, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prohance Generics:
There are no approved generic versions for Prohance as of now.
Alternative Brands for Prohance
Prohance which is used for enhancing contrast in MRI imaging., has several other brand drugs using the same active ingredient (Gadoteridol). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bracco |
|
About Prohance
Prohance is a drug owned by Bracco Diagnostics Inc. It is used for enhancing contrast in MRI imaging. Prohance uses Gadoteridol as an active ingredient. Prohance was launched by Bracco in 1992.
Approval Date:
Prohance was approved by FDA for market use on 16 November, 1992.
Active Ingredient:
Prohance uses Gadoteridol as the active ingredient. Check out other Drugs and Companies using Gadoteridol ingredient
Treatment:
Prohance is used for enhancing contrast in MRI imaging.
Dosage:
Prohance is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 279.3MG/ML | INJECTABLE | Prescription | INJECTION |